Chronic Obstructive Pulmonary Disease (Copd) Drugs Market - Global Industry Size, Share, Growth, Trends and Forecast 2016 - 2020
- Submitted by: Marketreport
- Views: 84
- Category: Other
- Date Submitted: 08/09/2016 03:42 AM
- Pages: 3
- Report this Essay
Technavio Announces the Publication of its Research Report Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the global chronic obstructive pulmonary disease (COPD) drugs market: AstraZeneca, Boehringer Ingelheim, Merck, and Novartis.
Other Prominent Vendors in the market are: Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, Asmacure, Astellas Pharma, BioMarck Pharmaceuticals, Chiesi Farmaceutici, Cytokinetics, F. Hoffmann-La Roche, Gilead Sciences, Innoviva, Invion, MediciNova, Mereo BioPharma, Mylan, Orion Corporation, Palobiofarma, Pearl Therapeutics, Pharmaxis, Prosonix, Pulmagen Therapeutics, RespiVert, SolAeroMed, Sunovion Pharmaceuticals, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention , Yungjin Pharm, and ZAI Lab.
Browse full report with TOC@ https://marketreportscenter.com/reports/344102/global-chronic-obstructive-pulmonary-disease-drugs-market-2016-2020
Commenting on the report, an analyst from Technavios team said: Innovative technologies for drug delivery will be one of the key trends for market growth. Vendors are investing heavily in R&D activities to design and develop innovative inhalers and nebulizers that are compact, portable, patient-friendly, and provide accurate results. The high efficiency of these devices also helps reduce the residual drug volume in the them when compared to other types of nebulizers. The advances in inhalers such as sensors, and the use of smartphone and tablets that can track and record the drug treatment dose have resulted in providing an interface between the physicians and patients.
According to the report, increase in smoking prevalence will be the key driver for market growth. Tobacco smoking is considered to be the leading cause of COPD, with 85% of the cases being because of this reason. The other 15% may be due to the exposure to second-hand smoke, air...
Technavio recognizes the following companies as the key players in the global chronic obstructive pulmonary disease (COPD) drugs market: AstraZeneca, Boehringer Ingelheim, Merck, and Novartis.
Other Prominent Vendors in the market are: Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, Asmacure, Astellas Pharma, BioMarck Pharmaceuticals, Chiesi Farmaceutici, Cytokinetics, F. Hoffmann-La Roche, Gilead Sciences, Innoviva, Invion, MediciNova, Mereo BioPharma, Mylan, Orion Corporation, Palobiofarma, Pearl Therapeutics, Pharmaxis, Prosonix, Pulmagen Therapeutics, RespiVert, SolAeroMed, Sunovion Pharmaceuticals, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention , Yungjin Pharm, and ZAI Lab.
Browse full report with TOC@ https://marketreportscenter.com/reports/344102/global-chronic-obstructive-pulmonary-disease-drugs-market-2016-2020
Commenting on the report, an analyst from Technavios team said: Innovative technologies for drug delivery will be one of the key trends for market growth. Vendors are investing heavily in R&D activities to design and develop innovative inhalers and nebulizers that are compact, portable, patient-friendly, and provide accurate results. The high efficiency of these devices also helps reduce the residual drug volume in the them when compared to other types of nebulizers. The advances in inhalers such as sensors, and the use of smartphone and tablets that can track and record the drug treatment dose have resulted in providing an interface between the physicians and patients.
According to the report, increase in smoking prevalence will be the key driver for market growth. Tobacco smoking is considered to be the leading cause of COPD, with 85% of the cases being because of this reason. The other 15% may be due to the exposure to second-hand smoke, air...